Compass Therapeutics (CMPX) Competitors $3.39 -0.29 (-7.88%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$3.45 +0.06 (+1.77%) As of 09/19/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CMPX vs. ADPT, MESO, DYN, HRMY, IMCR, APGE, SRPT, AUPH, CDTX, and VCELShould you be buying Compass Therapeutics stock or one of its competitors? The main competitors of Compass Therapeutics include Adaptive Biotechnologies (ADPT), Mesoblast (MESO), Dyne Therapeutics (DYN), Harmony Biosciences (HRMY), Immunocore (IMCR), Apogee Therapeutics (APGE), Sarepta Therapeutics (SRPT), Aurinia Pharmaceuticals (AUPH), Cidara Therapeutics (CDTX), and Vericel (VCEL). These companies are all part of the "pharmaceutical products" industry. Compass Therapeutics vs. Its Competitors Adaptive Biotechnologies Mesoblast Dyne Therapeutics Harmony Biosciences Immunocore Apogee Therapeutics Sarepta Therapeutics Aurinia Pharmaceuticals Cidara Therapeutics Vericel Adaptive Biotechnologies (NASDAQ:ADPT) and Compass Therapeutics (NASDAQ:CMPX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk. Do institutionals & insiders hold more shares of ADPT or CMPX? 99.2% of Adaptive Biotechnologies shares are held by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are held by institutional investors. 6.4% of Adaptive Biotechnologies shares are held by company insiders. Comparatively, 29.8% of Compass Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is ADPT or CMPX more profitable? Compass Therapeutics has a net margin of 0.00% compared to Adaptive Biotechnologies' net margin of -59.07%. Compass Therapeutics' return on equity of -53.11% beat Adaptive Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Adaptive Biotechnologies-59.07% -60.93% -23.03% Compass Therapeutics N/A -53.11%-46.14% Which has higher earnings and valuation, ADPT or CMPX? Compass Therapeutics has lower revenue, but higher earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdaptive Biotechnologies$178.96M11.37-$159.49M-$0.82-16.29Compass Therapeutics$850K551.49-$49.38M-$0.45-7.53 Does the media prefer ADPT or CMPX? In the previous week, Adaptive Biotechnologies had 7 more articles in the media than Compass Therapeutics. MarketBeat recorded 7 mentions for Adaptive Biotechnologies and 0 mentions for Compass Therapeutics. Adaptive Biotechnologies' average media sentiment score of 1.00 beat Compass Therapeutics' score of 0.00 indicating that Adaptive Biotechnologies is being referred to more favorably in the media. Company Overall Sentiment Adaptive Biotechnologies Positive Compass Therapeutics Neutral Do analysts rate ADPT or CMPX? Adaptive Biotechnologies presently has a consensus target price of $12.38, suggesting a potential downside of 7.37%. Compass Therapeutics has a consensus target price of $13.88, suggesting a potential upside of 309.29%. Given Compass Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Compass Therapeutics is more favorable than Adaptive Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adaptive Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88Compass Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Which has more volatility & risk, ADPT or CMPX? Adaptive Biotechnologies has a beta of 1.93, meaning that its stock price is 93% more volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500. SummaryCompass Therapeutics beats Adaptive Biotechnologies on 11 of the 17 factors compared between the two stocks. Get Compass Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CMPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMPX vs. The Competition Export to ExcelMetricCompass TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$508.88M$3.16B$5.80B$10.40BDividend YieldN/A2.37%5.63%4.60%P/E Ratio-7.5320.7876.8226.78Price / Sales551.49447.76532.95124.28Price / CashN/A46.6037.9961.55Price / Book3.739.6613.746.40Net Income-$49.38M-$53.13M$3.30B$271.80M7 Day Performance-5.04%3.11%2.65%3.48%1 Month Performance21.94%7.56%6.04%9.89%1 Year Performance104.22%11.15%80.14%28.51% Compass Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMPXCompass Therapeutics1.9208 of 5 stars$3.39-7.9%$13.88+309.3%+96.0%$508.88M$850K-7.5320Gap UpHigh Trading VolumeADPTAdaptive Biotechnologies3.5156 of 5 stars$13.08+3.7%$12.38-5.4%+179.5%$1.92B$205.22M-15.95790Positive NewsMESOMesoblast0.9475 of 5 stars$15.46+4.3%$18.00+16.4%+165.4%$1.90B$17.20M0.0080News CoverageDYNDyne Therapeutics3.673 of 5 stars$12.86-2.2%$34.07+164.9%-63.9%$1.87BN/A-3.33100HRMYHarmony Biosciences4.5617 of 5 stars$32.50+0.3%$51.00+56.9%-16.5%$1.86B$714.73M10.48200Positive NewsAnalyst UpgradeIMCRImmunocore2.1383 of 5 stars$34.42-2.3%$56.89+65.3%-4.7%$1.78B$310.20M-86.05320Analyst ForecastInsider TradeAPGEApogee Therapeutics2.8041 of 5 stars$36.86-0.1%$97.29+163.9%-31.0%$1.70BN/A-8.9291Positive NewsSRPTSarepta Therapeutics4.3327 of 5 stars$17.47+0.5%$39.32+125.1%-86.3%$1.70B$1.90B-20.081,372AUPHAurinia Pharmaceuticals2.5143 of 5 stars$12.81+0.5%$12.00-6.3%+80.6%$1.68B$235.13M29.79300CDTXCidara Therapeutics3.0461 of 5 stars$66.91+2.0%$64.14-4.1%+486.3%$1.66B$1.27M-6.0190High Trading VolumeVCELVericel2.8487 of 5 stars$31.42-2.4%$60.40+92.2%-34.0%$1.62B$237.22M261.86300News CoverageAnalyst DowngradeGap Up Related Companies and Tools Related Companies ADPT Alternatives MESO Alternatives DYN Alternatives HRMY Alternatives IMCR Alternatives APGE Alternatives SRPT Alternatives AUPH Alternatives CDTX Alternatives VCEL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CMPX) was last updated on 9/20/2025 by MarketBeat.com Staff From Our PartnersCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredGold Sets New Record After Fed Rate Cut. What’s Next?The Fed’s latest rate cut sent gold soaring past $3,700 — but history shows the biggest winners in gold bull m...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compass Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compass Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
